Quality is our legacy     
.
Site Language
.
.

.
 Search 
   Home
 
SEDICO Company
About SEDICO
News and Reports
Worldwide Presence
Careers at SEDICO
 
SEDICO products
Products List
Strategic Brands
Search for a product
 
Social Contribution
Diabetes Center
R&D
Caring for community
Access for medicines
 
Contact SEDICO
Contact Us
Distributors Log in
Partners Log in
Vendors Log in
Physicians Log in
Patients Log in
 
SEDICO Newsletter
Subscribe to SEDICO News

   Enter Your E-mail
 

Physician
Patient

Frequently Asked Questions about Rapido

 

As a derivative of Terfenadine; does Rapido (Fexofenadine) has the same side effects of Terfenadine?
Rapido (Fexofenadine) is the active metabolite of Terfenadine, It resembles Terfenadine only in its powerful action but it doesn’t cause the side effects; for example Fexofenadine has no serious drug interactions with Erythromycin and Ketoconazole. Also there are no E.C.G. changes (increase QT intervals) even in very high dose.
 

 

What about the safety of Rapido (Fexofenadine) in elderly patients?
Peak plasma levels of Fexofenadine are greater in geriatrics (over 65 years), but elimination half life is similar to that in younger age.
No change in pharmacokinetics of Fexofenadine in patients with hepatic impairment (5 % of the total dose is metabolized in liver) .
Renal impairment the rate of excretion & elimination half life was prolonged in those patients, generally the product is well tolerated in elderly patients.
 

Back

 

© 2004 Sedico Co. All rights reserved
Designed and Developed by EBM Co.